As to immunohistochemistry, the tumor cells were positively immunoreactive for CD5 in 10 (71.4%) patients, partial positively in 2 (14.3%) patients and weakly positively in 2 (14.3%) patients. The gene discussed is CD5; the disease is neoplasm.